News
3 Bright Spots in Merck's Q3 Results
You only had to look at Merck's (NYSE: MRK) stock movement to know that the big drugmaker's third-quarter results weren't too great. Merck's share price dropped after the company reported a 2%....
3 High-Yield Dividend Aristocrat Stocks
If dividend stocks were like golf, there would be an elite group of stocks with green jackets like golfing greats who win the Masters tournament get to wear. This group of winners is called the....
Vertex Pharmaceuticals Incorporated: One Eye on Earnings, One on the Pipeline
Vertex Pharmaceuticals (NASDAQ: VRTX) reported solid third-quarter earnings, with sales of its cystic fibrosis drugs up 34% year over year. Nevertheless, investors rightfully have one eye on the....
Celgene At $100: Buy, Sell, or Hold?
It's been a rotten couple of weeks to be a shareholder of Celgene (NASDAQ: CELG). The biotech giant's shares have been in near-freefall after they reached an all-time high of $147 on Oct. 2.....
3 Small-Cap Marijuana Stocks to Get on Your Radar
When it comes to the fastest-growing, and riskiest, industries in the stock market, none takes the cake like legal marijuana.According to cannabis research firm The Arcview Group, legal sales in....
Here's Why Endo International Stock Dropped as Much as 13.8% Today
Shares of generic pharma leader Endo International (NASDAQ: ENDP) sank nearly 14% today after the company announced two of its subsidiaries had filed a lawsuit against the U.S. Food and Drug....
ALPHA MOS : CHIFFRE D'AFFAIRES NEUF MOIS 2017
En M€ - Normes IFRS
Données non auditées
2017
2016
Variation
Chiffre d'affaires 1er semestre
2,1
3,9
-47%
Chiffre d'affaires 3ème....
There's a Lot to Like in AbbVie's Q3 Update
AbbVie (NYSE: ABBV) has set a pattern in recent quarters of meeting or barely exceeding consensus analysts' earnings estimates. It's not that the big biotech hasn't performed well; rather,....
Quintiles IMS Holdings Is Firing on All Cylinders
Quintiles IMS Holdings (NYSE: Q), a service and information provider for the healthcare and life sciences industries, reported its third-quarter results on Thursday, Oct. 26. The company's results....
3 Key Things to Watch in Pfizer's Q3 Results
There wasn't much to get excited about the last time Pfizer (NYSE: PFE) reported its quarterly results. While the big pharma company beat analysts' consensus earnings estimate, it also posted a 2%....
Stop Panicking About Celgene
Judging by the market reaction to Celgene's (NASDAQ: CELG) third-quarter results, you'd think one of the Four Horsemen of the Apocalypse just rode down Wall Street. Or maybe two of them....
Quantum Genomics reçoit le prix Galien MedStartUp pour le design innovant de son étude NEW-HOPE
Quantum Genomics (Euronext Growth - FR0011648971 – ALQGC), société biopharmaceutique spécialisée dans le développement d'une nouvelle classe de médicaments agissant directement sur le cerveau....
Quantum Genomics receives the Galien MedStartUp award for the innovative design of its NEW-HOPE study
Quantum Genomics (Euronext Growth – FR0011648971 – ALQGC), a biopharmaceutical company developing a new class of centrally-acting medication to treat hypertension and heart failure, announced....
Gilead Sciences Inc. Still Singing the HCV Blues in the 3rd Quarter
Surprisingly strong hepatitis C virus (HCV) sales helped Gilead Sciences (NASDAQ: GILD) enjoy better-than-expected results when the big biotech provided its second-quarter update in July. But that....
Was Celgene’s Third Quarter Really Crash-Worthy?
On the heels of reporting a disappointing late-stage trial failure, Celgene Corp. (NASDAQ: CELG) issued a poor third-quarter financial report that's stoking investors' fears. Has the biotech lost....
The Clear Reason Alkermes Plc's Shares Jumped by as Much as 12%
Shares of Alkermes (NASDAQ: ALKS), an Irish-based commercial-stage drug developer with a focus on central nervous system medicines, jumped by as much as 12% during Thursday's trading session and....
The Double Whammy That Sent Marijuana Stock Insys Therapeutics Crashing as Much as 30%
Shares of Insys Therapeutics (NASDAQ: INSY), a small-cap biotech with a focus on pain management, plunged as much as 30% on Wednesday after receiving a double whammy. One whammy was the arrest of....
Alkermes Reports Mixed Results, Updates Guidance
Alkermes (NASDAQ: ALKS), a commercial-stage biopharmaceutical company focused on diseases of the central nervous system, reported its third-quarter earnings results on Thursday, Oct. 26. While....
Should You Be Worried After Bristol-Myers Squibb's Q3 Results?
It's been an up-and-down kind of year for Bristol-Myers Squibb (NYSE: BMY). Early in 2017, investors were concerned after the company opted not to pursue accelerated approval for a combination of....
3 Dividend Stocks Perfect for Retirement
Retirement is a time to shift one's investment portfolio to a more defensive posture. If this can be done while generating income via dividend payouts, so much the better. We asked three of our....
Why Celgene Corporation Tumbled Today
Celgene (NASDAQ: CELG) is down 18.2% at 12:11 p.m. Thursday after releasing third-quarter earnings. It wasn't so much third-quarter revenue, which was up 10% year over year, or the adjusted....
Here's Why Idera Pharmaceuticals Plunged as Much as 35% Today
Shares of pre-revenue biopharma Idera Pharmaceuticals (NASDAQ: IDRA) sank as much as 35% this morning after the company announced the pricing of a major public stock offering. The company will....
3 Companies Tackling the Antibiotic-Resistant Bacteria Crisis
Antibiotics have saved countless lives since they were discovered nearly 90 years ago. However, decades of overuse have caused some bacteria to evolve antibiotic resistance, which poses a huge....
5 Intriguing Things Illumina's Management Said in Its Q3 Update
"Let the good times roll" might be a good theme for Illumina (NASDAQ: ILMN) in 2017. The gene-sequencing pioneer reported its third-quarter results on Tuesday. Illumina once again beat....
3 Value Stocks for Smart Investors
Everyone loves a good bargain, whether it be at the local store or, for smart investors, on Wall Street. And though we are well into a secular bull market that has lasted practically since the....